Bharat Serums to conduct drug trials for treatment of Covid-19 patients

Rozana Spokesman

News, Nation

Bharat Serum and Vaccine Limited (BSVL) have received approval from the Indian Pharmaceutical Regulator to test the pre-existing Ulinastatin

File Photo
File Photo

New Delhi: Bharat Serum and Vaccine Limited (BSVL) have received approval from the Indian Pharmaceutical Regulator to test the pre-existing Ulinastatin drug on 19 patients with severe Covid disease. This drug will be tested as a possible treatment for corona virus.

BSVL said in a statement that its Indian Pharmaceutical Regulatory Commission (DCGI) has approved a third phase of Ulinastatin in Covid patients with mild to moderate respiratory illness, i.e. ARDS.